Chiesi Ready To Reap Benefits Of Rare Disease Expansion
Amryt Buy Will Boost 2023 Sales
The Italian drugmaker has reported strong sales for 2022 driven by its respiratory drugs but this year will see a more prominent contribution from its rare disease offerings.
You may also be interested in...
The once-daily oral somatostatin receptor type 2 (SST2) agonist outshined placebo in patients switching from standard of care, offering an attractive alternative to once-monthly injectables.
Amryt’s Filsuvez Wins English Funding For Butterfly Skin Disease, Sanofi’s Dupixent Rejected In New Indication
Amryt/Chiesi’s birch bark extract gel, Filsuvez, is the first ever treatment for epidermolysis bullosa, a group of rare skin disorders, to be recommended by NICE for English reimbursement.
Agreement with Alexion is JCR’s first international deal for its blood-brain barrier drug delivery technology. Sartoris buys PolyPlus from private equity investors.